RenovoRx (NASDAQ:RNXT – Get Free Report) is expected to be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect RenovoRx to post earnings of ($0.12) per share for the quarter.
RenovoRx Stock Down 2.0 %
Shares of NASDAQ RNXT opened at $1.00 on Monday. The business has a fifty day simple moving average of $1.12 and a 200-day simple moving average of $1.15. The company has a market cap of $24.00 million, a price-to-earnings ratio of -1.75 and a beta of 1.15. RenovoRx has a 12 month low of $0.77 and a 12 month high of $1.69.
Analysts Set New Price Targets
Several research analysts have commented on RNXT shares. Ascendiant Capital Markets raised their target price on shares of RenovoRx from $8.25 to $9.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th. HC Wainwright assumed coverage on shares of RenovoRx in a research report on Thursday. They issued a “buy” rating and a $3.00 price target for the company.
About RenovoRx
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
See Also
- Five stocks we like better than RenovoRx
- Breakout Stocks: What They Are and How to Identify Them
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- What is Put Option Volume?
- MarketBeat Week in Review – 03/24 – 03/28
- What Are Dividend Achievers? An Introduction
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
